ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

アルプロスタジル

Alprostadil

HCID 5280723
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
745-65-3
標準SMILES
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O
InChIKey
GMVPRGQOIOIIMI-DWKJAMRDSA-N
分子式
C20H34O5
平均分子量
354.5 g/mol
単同位体質量
354.24062418

概要

Prostaglandin E1 is a prostaglandins E. It has a role as a vasodilator agent, an anticoagulant, a platelet aggregation inhibitor and a human metabolite. It is a conjugate acid of a prostaglandin E1(1-).

名称と識別子

優先名称
Alprostadil
IUPAC
7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
現地名
アルプロスタジル
英語名
Prostaglandin E1
分子式
C20H34O5
分子量
354.48

名称と別名

alprostadilProstaglandin E1745-65-3PGE1CaverjectEdexMuseAlprostadilumBefarProstin VR PediatricVitarosPrink
名称をさらに表示
リプルプロスタグランジンE1プロスチンVRペジアトリック(8R,13E,15S)-11α,15-ジヒドロキシ-9-オキソプロスタ-13-エン-1-酸(13E,15S)-11α,15-ジヒドロキシ-9-オキソプロスタ-13-エン-1-酸パルックスリポプロスタグランジンE1アリプロスト(-)-プロスタグランジンE11-プロスタグランジンE1(1R,2R,3R)-3-ヒドロキシ-2-[(E,3S)-3-ヒドロキシ-1-オクテニル]-5-オキソシクロペンタンヘプタン酸(+)-プロスタグランシンE1アルプロスタジルパルクスプリンクプロスタバシン7-[(1R,2R,3R)-3-ヒドロキシ-2-[(1E,3S)-3-ヒドロキシ-1-オクテニル]-5-オキソシクロペンチル]ヘプタン酸プロスタンディン(8S,11S,12S,13E,15R)-11,15-ジヒドロキシ-9-オキソプロスタ-13-エン-1-酸プロスタグランジンE1, 99%Alprostadil (PGE1)Prost-13-en-1-oic acidProstaglandine E1PGElLiplePalux
PGE-1Prostavasin(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acidCaverject ImpulsePGE1alphaDTXSID9022578Lipo PGE1Prostaglandin E1alpha

物性

構造計算による物性

XLogP
3.2
極性表面積
94.8 Ų
水素結合供与体数
3
水素結合受容体数
5
回転可能結合数
13
重原子数
25
形式電荷
0
複雑度
432

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
LipidsFatty Acyls [FA] -> Eicosanoids [FA03] -> Prostaglandins [FA0301]
LogP3.20
Human Drugs · 2 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point · 2 件

115-116 °C

115 - 116 °C

Physical DescriptionSolid
Dissociation Constants · 2 件

4.87

4.85 (at 25 °C)

Collision Cross Section · 2 件

190.6 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Calculation: Single Field; Dataset: Oxylipins]

181.94 Ų [M-H2O-H]- [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

物理化学的性質

融点
115 · 115-116 °C

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P264, P270, P280, P301+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 74 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 3 (100%)

毒性情報

Adverse EffectsAdverse Effects of Intraurethral Alprostadil Suppositories (MUSE)
Toxicity Summary · 1 件

The use of alprostadil for the treatment of erectile dysfunction in males may lead to prolonged erections and, in some cases, priapism. The incidence of priapism as an adverse effect of alprostadil is more common with the intraurethral suppository. This condition can also occur when unauthorized combination therapy is used or when patients exceed the prescribed dosage.

安全データ

F
8-10
wgk
3
rtecs
GY4569800
ridadr
UN 2811 6.1/PG 3
hs_code
29375000
risk_code
22-36/37/38-61
hazard_code
Xn,Xi
safety_code
36-26
hazard_class

化学と産業

薬理情報

ATC Code · 5 件

G04BE01

G - Genito urinary system and sex hormones

C - Cardiovascular system

QG - Genito urinary system and sex hormones

QC - Cardiovascular system

Protein BindingAlprostadil is bound in plasma primarily to albumin (81% bound) and, to a lesser extent, alpha-globulin IV-4 fraction (55% bound).
Pharmacodynamics · 1 件

Prostaglandin E1 is produced endogenously to relax vascular smooth muscle and cause vasodilation. As a synthetic form of prostaglandin E1, alprostadil has the same pharmacodynamic effects. Alprostadil inhibits platelet aggregation, has anti-inflammatory effects, interferes with immune responses, and stimulates factor X, a blood coagulation enzyme. In adult males, the use of alprostadil may lead to prolonged erection and priapism, penile fibrosis, hypotension, and injection site bleeding. In patients treated up to 24 months with alprostadil, the incidence of prolonged erections (>4 hours long) was 4% of all, and the incidence of priapism (erections greater than 6 hours in duration) was <1%. Patients with preexisting cardiovascular disease treated with alprostadil may also have higher cardiac risk. Neonates with congenital heart defects treated with alprostadil may experience apnea. Apnea is experienced by 10-12% of neonates and is more common in those weighing less than 2 kg at birth. The administration of alprostadil to neonates may also result in gastric outlet obstruction secondary to antral hyperplasia.

Mechanism of Action · 1 件

Alprostadil is a smooth muscle relaxant that promotes vasodilation and platelet aggregation inhibition. In neonatal patients with ductus arteriosus patency, alprostadil relaxes the ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This results in increased pulmonary or systemic blood flow in infants. Alprostadil appears to be most effective within 96 hours after birth since the DA rapidly loses its responsiveness to alprostadil. When administered by intracavernosal injection or as an intraurethral suppository, alprostadil acts locally to relax the trabecular smooth muscle of the corpora cavernosa and the cavernosal arteries. Swelling, elongation, and rigidity of the penis result when arterial blood rapidly flows into the corpus cavernosum to expand the lacunar spaces. The entrapped blood reduces the venous blood outflow as sinusoids compress against the tunica albuginea leading to penile rigidity. This is referred to as the corporal veno-occlusive mechanism.

関連反応

18 件
反応記録を作成
HRID 26304 の反応式
HRID 26304反応物として
HRID 46949 の反応式
HRID 46949反応物として
HRID 329226 の反応式
HRID 329226反応物として
HRID 437096 の反応式
HRID 437096反応物として
HRID 462132 の反応式
HRID 462132反応物として
HRID 866499 の反応式
HRID 866499反応物として
HRID 866500 の反応式
HRID 866500反応物として
HRID 866665 の反応式
HRID 866665反応物として
前へ1 / 3 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
745-65-3
PubChem CID
5280723
DTXSID
DTXSID9022578
ChEMBL
CHEMBL495
ChEBI
CHEBI:15544
UNII
F5TD010360
EC Number
212-017-2
Nikkaji
J3.319G
比旋光度
-64 · -64 º (c=1.0, C2H5OH)
沸点
407.69 °C · 407.69°C (rough estimate)
比重(密度)
1.0458 · 1.0458 (rough estimate)
屈折率
1.612 · 1.6120 (estimate)
貯蔵温度
-20 °C · -20°C
溶解性
1 mg/mL · エタノール: 1 mg/mL
酸解離定数(Pka)
4.85 · pKa 4.85± 0.07(H2O,t=25±0.1,I=0.1(NaCl)) (Uncertain)
外見
粉
色
ホワイトからオフホワイト
由来生物
synthetic (organic)
水溶解度
不溶性
Merck
13 · 13,7968
BRN
5294062 · 5294062
安定性
-20 °Cで最大1か月保存できます。 · DMSO溶液またはエタノール溶液で-20°Cで最大1か月保存できます。
InChI
1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
InChIKey
GMVPRGQOIOIIMI-DWKJAMRDSA-N
SMILES
O=C1[C@H](CCCCCCC(O)=O)[C@@H](/C=C/[C@H](CCCCC)O)[C@H](O)C1

化学的性質

化学的特性Crystalline Solid

6.1(b)
packing_group
III
Hazard Classifications
Acute Tox. 3 Oral
ストレージクラス
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Biological Half-LifeIn healthy adults and neonates given a single intravenous dose of alprostadil, half-life goes from 5 to 10 minutes.
Metabolism/Metabolites · 1 件

Alprostadil is rapidly metabolized in the human body. Following intracavernous administration, alprostadil is metabolized in the corpus cavernosum, and a smaller portion is absorbed from the penis into systemic circulation. After intravenous or arterial administration, alprostadil is metabolized and distributed throughout the entire body except for the central nervous system. As much as 60-90% of the circulating alprostadil may be metabolized in the lungs through first-pass pulmonary elimination, in a process known as beta- and omega-oxidation. The enzymatic oxidation of the C15-hydroxy group of alprostadil leads to the formation of 15-keto-PGE<sub>1</sub>, while the reduction of the C13, 14-double bond produces 15-keto-PGE<sub>0</sub>, and 13,14-dihydro-PGE<sub>1</sub> (PGE<sub>0</sub>). The 15-keto metabolites are inactive, but the PGE<sub>0</sub> metabolite has a similar potency to alprostadil in isolated animal organs. The major metabolite of alprostadil is 15-keto-PGE<sub>0</sub>.

FDA Pharmacological Classification · 6 件

F5TD010360

ALPROSTADIL

Physiologic Effects [PE] - Genitourinary Arterial Vasodilation

Established Pharmacologic Class [EPC] - Prostaglandin Analog

Established Pharmacologic Class [EPC] - Prostaglandin E1 Agonist

Mechanisms of Action [MoA] - Prostaglandin Receptor Agonists

MeSH Pharmacological Classification · 3 件

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

Drugs used to cause dilation of the blood vessels.

Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS.

Absorption, Distribution and Excretion · 4 件

In patients with erectile dysfunction given 20 μg of alprostadil intracavernously, the systemic plasma concentrations of prostaglandin E1 increased from a baseline of 0.8 pg/mL to a Cmax of 16.8 pg/mL (corrected for baseline). The tmax and AUC for this group of patients were 4.8 min and 173 pg⋅min/mL, respectively. In patients given 20 μg of alprostadil intravenously, AUC was similar to the one detected in patients that received alprostadil intracavernously (174 pg⋅min/mL); however, they had a higher tmax (25.5 min) and a lower Cmax (7.09 pg/mL). Compared to the same dose given by a short-term intravenous infusion, the absolute bioavailability of alprostadil estimated from systemic exposure was about 98%.

Following the degradation of alprostadil by beta- and omega-oxidation, metabolites are excreted primarily by the kidney, and excretion is essentially complete within 24 hours after administration (92%). Approximately 88% and 12% of alprostadil metabolites are excreted through urine and feces, respectively, over 72 hours. Alprostadil and its metabolites are not retained in tissues, and unchanged alprostadil has not been detected in urine.

The volume of distribution of alprostadil has yet to be determined.

In patients with erectile dysfunction given an intravenous infusion of alprostadil (20 μg), the total body clearance was 115 L/min.

Tissue LocationsEpidermis
Cellular LocationsCytoplasm
応用分野 · 3 件

説明Prostaglandin E1 is an endogenous prostaglandin with vasodilatory, anti-platelet, and anti-hypertensive activities. It is in clinical use for the treatment of erectile dysfunction and the emergency management of infants with patent ductus arteriosus. It has also been used in the treatment of peripheral arterial occlusive disease (PAD).

使用A primary Prostaglandin; easily crystallized from purified biological extracts. Vasodilator (peripheral)

一般的な説明PGE1, Alprostadil (Prostin VR Pediatric), is a naturally occurring prostaglandin that has found particular use in maintaining a patent (opened) ductus arteriosus in infants with congenital defects that restrict pulmonary or systemic blood flow. Alprostadil must be administered intravenously continually at a rate of approximately 0.1 μg/kg/min to maintain the patency of the ductus arteriosus until corrective surgery can be performed. Up to 80% of circulating alprostadil may be metabolized in a single pass through the lungs. Because apnea has been observed in 10% to 12% of neonates with congenital heart defects, this product should be administered only when ventilatory assistance is immediately available. Other commonly observed side effects include decreased arterial blood pressure, which should be monitored during infusion; inhibited platelet aggregation, which might aggravate bleeding tendencies; and diarrhea.

上流・下流製品情報

上流原料

2-ブトキシエチルメタクリラート硝酸銀γ-リノレン酸メチルグルタチオンシクロペンテン水素アラキドン酸ジノプロストンEthyl acetate solution過よう素酸ナトリウムエチレングリコールナトリウムメトキシドp-トルエンスルホン酸一水和物カリウム tert-ブトキシド水素化ナトリウム四酸化オスミウム (4%水溶液)(13E,15S)-11α,15-ジヒドロキシ-9-オキソプロスタ-13-エン-1-酸メチル(2R,3S)-1,2-Epoxy-3-hydroxy-4-pentene